Enanta Pharmaceuticals, Inc.ENTANASDAQ
LOADING
|||
EPS Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year earnings per share growth rate
Latest
-2.35%
↓ 174% below average
Average (39q)
3.18%
Historical baseline
Range
High:534.09%
Low:-174.55%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | -2.35% |
| Q2 2025 | 19.81% |
| Q1 2025 | -0.95% |
| Q4 2024 | 22.79% |
| Q3 2024 | -27.10% |
| Q2 2024 | 27.21% |
| Q1 2024 | 6.96% |
| Q4 2023 | -18.80% |
| Q3 2023 | 28.49% |
| Q2 2023 | -3.91% |
| Q1 2023 | -28.78% |
| Q4 2022 | -8.59% |
| Q3 2022 | 16.34% |
| Q2 2022 | 5.56% |
| Q1 2022 | -9.46% |
| Q4 2021 | -21.31% |
| Q3 2021 | -2.52% |
| Q2 2021 | -9.17% |
| Q1 2021 | -165.85% |
| Q4 2020 | 71.92% |
| Q3 2020 | -105.63% |
| Q2 2020 | -136.67% |
| Q1 2020 | -144.12% |
| Q4 2019 | 44.68% |
| Q3 2019 | 30.56% |
| Q2 2019 | 71.43% |
| Q1 2019 | -84.33% |
| Q4 2018 | -4.96% |
| Q3 2018 | 34.29% |
| Q2 2018 | 61.54% |
| Q1 2018 | 6.56% |
| Q4 2017 | -68.06% |
| Q3 2017 | 534.09% |
| Q2 2017 | -57.14% |
| Q1 2017 | -7.69% |
| Q4 2016 | -174.55% |
| Q3 2016 | -67.02% |
| Q2 2016 | 37.00% |
| Q1 2016 | -106.47% |
| Q4 2015 | 363.33% |